On October 20, 2025, EDAP TMS SA announced that it has entered into a €36 million multi‑tranche credit facility with the European Investment Bank (EIB). The facility is intended to support the global expansion of the company’s Focal One® Robotic High‑Intensity Focused Ultrasound (HIFU) platform and to accelerate the development of new clinical indications.
The credit facility will be drawn in multiple tranches, with the first tranche of €11 million expected to be accessed in the fourth quarter of 2025. The proceeds will be used to fund continued worldwide deployment of Focal One® and to expedite research and development for additional therapeutic applications.
CEO Ryan Rhodes said, "This Credit Facility provides EDAP with an important source of strategic growth capital," while EIB Vice‑President Ambroise Fayolle noted that the bank is pleased to support the next development phase of the Lyon‑based company and its innovative robotic HIFU technology for prostate cancer and endometriosis.
The new financing strengthens EDAP’s balance sheet, giving it additional liquidity to pursue aggressive market penetration and product expansion. By securing low‑interest capital, the company can accelerate revenue growth from its high‑margin HIFU business and potentially increase its share of the expanding focal therapy market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.